ADARx Debuts After Upsized $446 Million IPO, the Third-Largest Biotech Listing of 2026

What happened

ADARx Pharmaceuticals, a developer of siRNA medicines, began trading on Friday, Sept. 25, after pricing an upsized initial public offering at $17 per share late on Sept. 24. According to BioSpace, the company raised $446.3 million, well above its earlier target of $318.6 million at an estimated $16 per share.

The offering is the third-largest biotech IPO of 2026, behind Parabilis Medicines’ $670 million listing and Kailera Therapeutics’ $625 million listing, BioSpace reported. It is the 27th biotech IPO of the year.

Offering details

• Shares: 26.25 million shares of common stock.
• Price: $17 per share, above the $16 per share assumed in its earlier filing.
• Gross proceeds: $446.3 million.
• Underwriter option: Up to 3.9 million additional shares within 30 days.
• Ticker: ADRX, according to Renaissance Capital.
• Strategic investor: AbbVie’s concurrent private placement will give it about 4.9% of ADARx’s outstanding shares after closing.

AbbVie already has a commercial relationship with the company. BioSpace noted that AbbVie licensed an ADARx program in 2025 with $335 million upfront.

Pipeline

ADARx’s most mature asset, onvuzosiran, is moving into Phase 3 testing in hereditary angioedema, with topline data expected by the end of 2027. Its lead siRNA candidate agazisiran, which targets complement factor B, is headed into mid-stage studies for several complement-mediated diseases.

Small interfering RNA drugs work by silencing the production of specific disease-causing proteins in the liver or other tissues. They are typically given by injection at long intervals, which has made them attractive for chronic conditions where infrequent dosing can improve adherence.

Why it matters for the sector

The size and pricing of the deal point to strong investor demand for late-stage RNA medicines companies. Increasing both the share count and the price above earlier assumptions is generally a sign of strong demand in the order book. A strategic investment from a large pharma partner can also reassure IPO buyers about the quality of a company’s science.

The listing comes during a more active year for biotech IPOs than the previous several. Large raises such as those by Parabilis, Kailera and now ADARx show that public investors are again willing to fund companies with clinical-stage pipelines at scale, though aftermarket performance has been mixed across the class.

RNA interference has been one of the more validated drug platforms of the past decade, with several approved products. New entrants such as ADARx and City Therapeutics, which filed for its own IPO the day before ADARx’s debut according to BioSpace, are betting that investors will continue to fund the next generation of RNA companies.

For ADARx, the capital supports a Phase 3 program in hereditary angioedema, a market that has seen several new therapies in recent years, as well as mid-stage work in complement-mediated diseases.

The AbbVie stake also adds a long-term holder to the shareholder base. Strategic investments by partners at IPO are sometimes viewed as a signal of continued collaboration, though they do not by themselves guarantee future deals.

Large IPOs give companies enough cash to reach multiple data readouts without returning to the market quickly. That can reduce dilution risk for new shareholders, one reason investors have favored bigger, well-funded offerings in 2026.

What to watch

• Aftermarket trading of ADARx shares relative to the $17 IPO price.
• Exercise of the underwriters’ option to buy additional shares.
• Initiation of the onvuzosiran Phase 3 trial and progress of agazisiran.
• Pricing of City Therapeutics’ IPO and other RNA-focused listings.

This article is for information only and is not investment advice.

Sources: BioSpace, Renaissance Capital

How siRNA Medicines Work

Every protein the body makes starts as a messenger RNA copy of a gene. Small interfering RNA drugs take advantage of a natural process cells use to regulate those messages.

1. Delivery. The siRNA drug, a short double-stranded RNA, is injected and carried to target cells. For liver targets, many siRNA drugs are attached to a sugar-based molecule called GalNAc, which binds a receptor found on liver cells and helps them take up the drug.
2. Loading. Inside the cell, one strand of the siRNA is loaded into a protein complex known as RISC.
3. Recognition. The loaded strand guides the complex to the matching messenger RNA.
4. Silencing. The complex cuts the messenger RNA, so less of the disease-related protein is made.
5. Duration. Because the complex can act repeatedly, a single dose can reduce protein levels for weeks or months, enabling infrequent dosing.

A Primer on the Complement System

The complement system is a group of blood proteins that form part of the body’s innate immune defense. When triggered, these proteins work in a cascade to tag pathogens, recruit immune cells and damage invading microbes. Complement factor B is a component of the alternative pathway, one of the cascade’s main routes, which can amplify the response.

When complement is overactive or poorly regulated, it can damage the body’s own cells. Complement-mediated diseases include certain blood disorders and kidney and eye conditions. Reducing levels of a key component such as factor B is one strategy for dampening an overactive cascade. The trade-off developers must manage is infection risk, since complement also protects against certain bacteria, which is why vaccination requirements often accompany complement-blocking therapies. Patients should discuss any condition and treatment with their own physicians.

Understanding a Concurrent Private Placement

In a concurrent private placement, an investor buys shares directly from the company at the same time as the IPO, outside the public offering. Strategic partners often use this route to acquire a defined stake without competing for shares in the public book. For the company, it adds proceeds and signals partner support. For IPO buyers, a partner’s stake is often seen as a vote of confidence, though it does not by itself guarantee future deals or results.

Questions Readers Ask

What does “upsized” mean?

The company sold more shares than originally planned, typically because investor demand exceeded the initial offering size.

Why is a stake just under 5% common?

In the United States, investors that cross 5% ownership of a public company face additional reporting requirements, so stakes are sometimes sized just below that level.

What is topline data?

The first summary of a trial’s main results, usually released before full detailed findings are presented or published.

Why do infrequent doses matter for chronic diseases?

Medicines that must be taken daily for years can be hard to stick with. A treatment given every few months may be easier for patients to stay on, which can influence both outcomes and how physicians and payers view a product.

This article is for general information only and is not investment or medical advice.